MCRB
HealthcareSeres Therapeutics, Inc.
$15.19
+$0.04 (+0.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Seres Therapeutics, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $137.42 million and approximately 103 employees. It operates in the biotechnology industry. The company's financial health is marked by significant losses, as evident from its net income and EBITDA figures. The company reported a net income of $5.39 million on revenue of $351,000, resulting in an operating margin of -6403.7%. Its return on equity stands at 16.0%, while the return on assets is -40.1%. Seres Therapeutics also has a substantial debt-to-equity ratio of 195.10 and cash reserves of $47.64 million. The company's valuation metrics are notable, with a forward P/E ratio of -1.46 and an EV/EBITDA of -1.76. The price to sales ratio is significantly high at 391.50, and the gross margin is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $137.42M
- P/E Ratio
- 17.26
- 52-Week High
- $29.98
- 52-Week Low
- $6.53
- Avg Volume
- 165.16K
- Beta
- 0.23
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 103